Katarina Lindahl

Katarina Lindahl

Auto-generated profile, based on publicly available information

Katarina Lindahl

Department of Medical Sciences, Uppsala University, Uppsala, Sweden

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2015 in European Journal of Human Genetics
Verified
Journal Article
Closed access
KLKatarina Lindahl
Katarina Lindahl
EÅEva Åström
Eva Åström
CRCarl-Johan Rubin
Carl-Johan Rubin
GGGiedre Grigelioniene
Giedre Grigelioniene
BMBarbro Malmgren
Barbro Malmgren
AKAndreas Kindmark
Andreas Kindmark

1 June 2016 in Bone
Verified
Journal Article
Closed access
KLK. Lindahl
K. Lindahl
AKA. Kindmark
A. Kindmark
CRC.-J. Rubin
C.-J. Rubin
BMB. Malmgren
B. Malmgren
GGG. Grigelioniene
G. Grigelioniene
EÅE. Åström
E. Åström

1 September 2018 in Bone
Verified
Journal Article
Closed access
KLKatarina Lindahl
Katarina Lindahl
EÅEva Åström
Eva Åström
ADAnca Dragomir
Anca Dragomir
SSSofie Symoens
Sofie Symoens
PCPaul Coucke
Paul Coucke
AKAndreas Kindmark
Andreas Kindmark

1 July 2009 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
KLKatarina Lindahl
Katarina Lindahl
CRCarl-Johan Rubin
Carl-Johan Rubin
HBHelena Brändström
Helena Brändström
MKMagnus K. Karlsson
Magnus K. Karlsson
AHAnna Holmberg
Anna Holmberg
ÖLÖsten Ljunggren
Östen Ljunggren

1 January 2013 in International Journal of Medical Sciences
Verified
Journal Article
Open access
KLKatarina Lindahl
Katarina Lindahl
AKAndreas Kindmark
Andreas Kindmark
NLNavya Laxman
Navya Laxman
EÅEva Åström
Eva Åström
CRCarl-Johan Rubin
Carl-Johan Rubin
ÖLÖsten Ljunggren
Östen Ljunggren
Osteogenesis imperfecta, also known as "brittle bone disease", is a heterogeneous disorder of connective tissue generally caused by dominant mutations in the genes COL1A1 and COL1A2, encoding the α1 and α2 chains of type I (pro)collagen. Symptomatic patients are usually prescribed bisphosphonates, but this treatment is neither curative nor sufficient. A promising field is gene silencing through RNA interference. In this study small interfering RNAs (siRNAs) were designed to target each allele of 3'UTR insertion/deletion polymorphisms (indels) in COL1A1 (rs3840870) and COL1A2 (rs3917). For both indels, the frequency of heterozygous individuals was determined to be approximately 50% in Swedish cohorts of healthy controls as well as in patients with osteogenesis imperfecta. Cultures of primary human bone derived cells were transfected with siRNAs through magnet-assisted transfection. cDNA from transfected cells was sequenced in order to measure targeted allele/non-targeted allele ratios and the overall degree of silencing was assessed by quantitative PCR. Successful allele dependent silencing was observed, with promising results for siRNAs complementary to both the insertion and non-insertion harboring alleles. In COL1A1 cDNA the indel allele ratios were shifted from 1 to 0.09 and 0.19 for the insertion and non-insertion allele respectively while the equivalent resulting ratios for COL1A2 were 0.05 and 0.01. Reductions in mRNA abundance were also demonstrated; in cells treated with siRNAs targeting the COL1A1 alleles the average COL1A1 mRNA levels were reduced 65% and 78% compared to negative control levels and in cells treated with COL1A2 siRNAs the average COL1A2 mRNA levels were decreased 26% and 49% of those observed in the corresponding negative controls. In conclusion, allele dependent silencing of collagen type I utilizing 3'UTR indels common in the general population constitutes a promising mutation independent therapeutic approach for osteogenesis imperfecta.

1 May 2013 in Bone Abstracts
Verified
Journal Article
Closed access
KLKatarina Lindahl
Katarina Lindahl
AKAndreas Kindmark
Andreas Kindmark
NLNavya Laxman
Navya Laxman
EAEva Aestrom
Eva Aestrom
CRCarl-Johan Rubin
Carl-Johan Rubin
OLOsten Ljunggren
Osten Ljunggren
Osteogenesis imperfecta, also known as ‘brittle bone disease’, is a heterogeneous disorder of connective tissue generally caused by dominant mutations in the genes COL1A1 and COL1A2, encoding the α1 and α2 chains of type I (pro)collagen. Symptomatic patients are usually prescribed bisphosphonates, but this treatment is neither curative nor sufficient. A promising field is gene silencing through RNA interference. In this study, small interfering RNAs (siRNAs) were designed to target each allele of 3′UTR insertion/deletion polymorphisms (indels) in COL1A1 (rs3840870) and COL1A2 (rs3917). For both indels, the frequency of heterozygous individuals was determined to be approximately 50% in Swedish cohorts of healthy controls as well as in patients with osteogenesis imperfecta. Cultures of primary human bone derived cells were transfected with siRNAs through magnet-assisted transfection. cDNA from transfected cells was sequenced in order to measure targeted allele:non-targeted allele ratios and the overall degree of silencing was assessed by quantitative PCR. Successful allele dependent silencing was observed, with promising results for siRNAs complementary to both the insertion and non-insertion harboring alleles. In COL1A1 cDNA the indel allele ratios were shifted from 1 to 0.08 and 0.19 for the insertion and non-insertion allele respectively while the equivalent resulting ratios for COL1A2 were 0.05 and 0.01. Reductions in mRNA abundance were also demonstrated; in cells treated with siRNAs targeting the COL1A1 alleles the average COL1A1 mRNA levels were reduced 65 and 78% compared to negative control levels and in cells treated with COL1A2 siRNAs the average COL1A2 mRNA levels were decreased 26 and 49% of those observed in the corresponding negative controls. In conclusion, allele dependent silencing of collagen type I utilizing 3′UTR indels common in the general population constitutes a promising mutation independent therapeutic approach for osteogenesis imperfecta.